Orchid Pharma Limited

As of June 30, 2026, Orchid Pharma Limited carries a market capitalization of 49.65B, placing it among publicly traded companies globally. Its enterprise value stands at 49.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Orchid Pharma Limited's next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Orchid Pharma Limited has 50.72M shares outstanding.

As of June 30, 2026, Orchid Pharma Limited trades at a trailing price-to-earnings ratio of 597.86.

As of June 30, 2026, Orchid Pharma Limited trades at an EV/EBITDA multiple of 44.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 67.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 49.65B versus a market cap of 49.65B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 6.53M in revenue per employee across its workforce of 1,443.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Orchid Pharma Limited recorded 740,000.00 in income tax expense. That works out to an effective tax rate of 0.74, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 99.55M, leaving 86.68M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Orchid Pharma Limited's stock has gained approximately 13.38% over the past 52 weeks. The 50-day moving average sits at 985.86, while the 200-day moving average is 810.23.

Over the twelve months ended June 30, 2026, Orchid Pharma Limited generated 9.43B in revenue and converted that into 86.68M in net income, yielding earnings per share of 1.52. EBITDA reached 1.11B, while operating income came in at 801.42M.

Over the twelve months ended June 30, 2026, Orchid Pharma Limited posted a gross margin of 33.02, reflecting its pricing power and cost economics. The operating margin of 8.50 and net profit margin of 0.92 provide insight into operational efficiency.

Orchid Pharma Limited's most recent stock split took place on September 15, 2005 with a 2:3 split ratio.